Monte Rosa Therapeutics Bolsa (NASDAQ: GLUE)

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.repay.com%2F&amp;esheet=54253223&amp;newsitemid=20250512240628&amp;lan=en-US&amp;anchor=Repay+Holdings+Corporation&amp;index=1&amp;md5=783b6ffe0ac9efd3ad9030dc0a71d354">Repay Holdings Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced that its Board of Directors has increased its authorized share repurchase program. The share repurchase program authorizes the Company to now purchase up to $75 million (up from $50 million) of the Company's Class A common stock. As of the date of this release, there remains approximately $61.2 million in capacity for share repurchases under the increased share repurchase program.

News

Buybacks

RPAY

REPAY  Authorizes The Company To Now Purchase Up To $75M, Up From $50M, Of The Company's Class A Common Stock

Earnings

Earnings Beats

ARCT

Arcturus Therapeutics Q1 EPS $(0.52) Beats $(1.33) Estimate, Sales $29.38M Beat $27.88M Estimate

Integral Ad Science Holdi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) raises FY2025 sales outlook from $588.00 million-$600.00 million to $590.00 million-$600.00 million vs $592.02 million estimate.

Guidance

Integral Ad Science Holdi Raises FY2025 Sales Guidance from $588.00M-$600.00M to $590.00M-$600.00M vs $592.02M Est

Amtech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>) reported quarterly losses of $(0.16) per share. This is a 1500 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $15.58 million which missed the analyst consensus estimate of $18.50 million by 15.78 percent. This is a 38.74 percent decrease over sales of $25.43 million the same period last year.

Earnings Misses

ASYS

Amtech Systems Q2 Adj. EPS $(0.16) Down From $(0.01) YoY, Sales $15.58M Miss $18.50M Estimate

Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) reported quarterly earnings of $0.17 per share which met the analyst consensus estimate. This is a 5.56 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $39.55 million which missed the analyst consensus estimate of $41.78 million by 5.33 percent. This is a 83.30 percent increase over sales of $21.58 million the same period last year.

VINP

Vinci Partners Inv Q1 Adj. EPS $0.17, Inline, Sales $39.55M Miss $41.78M Estimate

Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) sees Q2 sales of $1.800 million-$2.000 million vs $3.81 million analyst estimate.

PRSO

Peraso Sees Q2 Sales $1.800M-$2.000M vs $3.81M Est

Integral Ad Science Holdi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) sees Q2 sales of $142.000 million-$144.000 million vs $129.18 million analyst estimate.

Integral Ad Science Holdi Sees Q2 Sales $142.000M-$144.000M vs $129.18M Est

Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.16) by 50 percent. This is a 90.36 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $3.87 million which beat the analyst consensus estimate of $3.81 million by 1.67 percent. This is a 37.39 percent increase over sales of $2.82 million the same period last year.

Peraso Q1 Adj. EPS $(0.08) Beats $(0.16) Estimate, Sales $3.87M Beat $3.81M Estimate

Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 600 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $134.07 million which beat the analyst consensus estimate of $129.18 million by 3.78 percent. This is a 17.06 percent increase over sales of $114.53 million the same period last year.

Integral Ad Science Q1 EPS $0.05 Beats $0.03 Estimate, Sales $134.07M Beat $129.18M Estimate

American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) affirms FY2025 sales outlook from $650.00 million-$660.00 million to $650.00 million-$660.00 million vs $654.04 million estimate.

APEI

American Public Education Affirms FY2025 Sales Guidance of $650.00M-$660.00M vs $654.04M Est

American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is looking for Q2 GAAP EPS of $(0.13)-$(0.04) vs $0.15 analyst estimate. sees sales of $160.000 million-$162.000 million vs $161.73 million analyst estimate.

American Public Education Sees Q2 GAAP EPS $(0.13)-$(0.04) vs $0.15 Est; Sees Sales $160.000M-$162.000M vs $161.73M Est

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) affirms FY2025 sales outlook from $140.00 million-$155.00 million to $140.00 million-$155.00 million vs $149.32 million estimate.

KPTI

Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.00M-$155.00M vs $149.32M Est

Ampco-Pittsburgh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AP#NYSE">AP</a>) reported quarterly earnings of $0.06 per share. This is a 142.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported $104.27 million in sales this quarter. This is a 5.40 percent decrease over sales of $110.22 million the same period last year.

Ampco-Pittsburgh Q1 EPS $0.06 Up From $(0.14) YoY, Sales $104.27M Down From $110.22M YoY

PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.32 by 12.5 percent. This is a 9.68 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $61.94 million which missed the analyst consensus estimate of $62.89 million by 1.52 percent. This is a 39.64 percent increase over sales of $44.35 million the same period last year.

PFLT

PennantPark Floating Rate Q2 Adj. EPS $0.28 Misses $0.32 Estimate, Sales $61.94M Miss $62.89M Estimate

VSEE

VSee Health Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is unchanged from the same period last year. The company reported quarterly sales of $8.53 million which missed the analyst consensus estimate of $25.04 million by 65.92 percent. This is a 9.99 percent increase over sales of $7.76 million the same period last year.

NRGV

Energy Vault Holdings Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $8.53M Miss $25.04M Estimate

Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) reported quarterly losses of $(0.10) per share. This is a 75.61 percent increase over losses of $(0.41) per share from the same period last year. The company reported $24.73 million in sales this quarter. This is a 43.93 percent decrease over sales of $44.11 million the same period last year.

ACNT

Ascent Industries Q1 EPS $(0.10) Up From $(0.41) YoY, Sales $24.73M Down From $44.11M YoY

Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.22 by 45.45 percent. This is a 108.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $89.01 million which missed the analyst consensus estimate of $101.97 million by 12.71 percent. This is a 469.79 percent increase over sales of $15.62 million the same period last year.

RGNX

Regenxbio Q1 EPS $0.12 Misses $0.22 Estimate, Sales $89.01M Miss $101.97M Estimate

AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) and Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) stocks traded higher Monday after the U.S. and China agreed to a temporary reduction in most tariffs on <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">each other&#8217;s goods.</a>
What To Know: The trade deal will lower U.S. duties on Chinese goods from 145% to 30% and Chinese tariffs on U.S. imports from 125% to 10% for a three-month period, according to <a href="https://www.msn.com/en-us/money/markets/us-china-agree-to-lower-most-tariffs-for-90-days-amid-trade-talks/ar-AA1EAVhw?ocid=BingNewsSerp">The Washington Post</a>.
On the U.S. side, the talks were led by Trade Representative&nbsp;Jamieson Greer&nbsp;and Treasury Secretary&nbsp;Scott Bessent, while Vice Premier&nbsp;He Lifeng&nbsp;led the discussions for China.
Bessent said in a news conference, "The consensus from both delegations this weekend is that neither side wants a decoupling, and what had occurred with these very high tariffs was the equivalent of a trade embargo, and neither side wants that.&#8221; Bessent further added that both countries want more balanced trade.
The existing 30% U.S. tariff on Chinese goods consists of a 10% base rate plus a 20% additional tariff added by President Donald Trump in response to concerns over China's role in producing fentanyl-related chemicals.
The U.S. is also reportedly urging China to increase its purchases of American products.
Software stocks may be rising as the tariff reduction fuels optimism that improved U.S.-China relations could support global economic growth.
Price Action: Applovin stock closed 5.89% higher at $347.90, Salesforce shares closed 4.87% higher at $288.82, Datadog shares closed 5.14% higher at $113.42 and Atlassian stock closed 7.82% higher at $223.75.
See Also: 
 • <a href="https://www.benzinga.com/insights/earnings/25/05/45355288/a-look-ahead-acurx-pharmaceuticalss-earnings-forecast">A Look Ahead: Acurx Pharmaceuticals&#8217;s Earnings Forecast</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

Movers

Tech

DDOG

TEAM

AppLovin, Salesforce, Other Software Stocks Rally On Tariff Relief

Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.25 by 52 percent. This is a 7.32 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $41.38 million which beat the analyst consensus estimate of $40.52 million by 2.13 percent. This is a 12.13 percent increase over sales of $36.91 million the same period last year.

Natural Gas Services Gr Q1 EPS $0.38 Beats $0.25 Estimate, Sales $41.38M Beat $40.52M Estimate

Health Care

Press Releases

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Management

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

Comments

Monte Rosa Therapeutics

Noticias

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL